Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data

Key Points

• The study observes significant concordance between Ames and in vivo gene mutation assays for nitrosamines.
• Key evidence reveals a robust dose-response relationship linked to carcinogenic effects.
• Analysis using in vivo transgenic rodent models helps assess gene mutation related to NDSRIs more accurately.
• This work highlights cross-assay relevance for assessing mutagenicity, suggesting further research on potency evaluation.